San Gabriel Valley Tribune

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare...

1 Healthcare Stock to Research Further and 2 Facing Headwinds

January 29, 2026

Netflix may be forced to offer all cash for WBD if the cable assets being spun off don't have the value Netflix thought they did. But is that something Netflix will do, and what are the risks?

Topics Stocks

Will Netflix Go All-Cash for WBD? ↗

January 29, 2026

Topics Artificial Intelligence

Why Is HIMS Stock Slipping Premarket Today? ↗

January 12, 2026

Hims & Hers CEO Bets On Personalized Healthcare And AI In 2026 — Wall Street Braces For A Costly Year ↗

January 09, 2026

When you find winning stocks, stick with them.

Topics Artificial Intelligence

2 Top Stocks to Double Up On Right Now ↗

January 20, 2026

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 2.2% in the morning session after Morgan Stanley reiterated its Equalweight rating but voiced concerns about the company's slowing...

Topics Artificial Intelligence

Why Hims & Hers Health (HIMS) Stock Is Down Today

January 20, 2026

Nasdaq, S&P 500 Futures Wobble As Trump-Powell Clash Rattles Markets: Why CRML, HIMS, WMT, NFLX, NVAX, COF Are On Traders' Radar Today ↗

Topics Artificial Intelligence

January 12, 2026

Are you looking for investment opportunities in 2026?

Topics Stocks

Stocks to Love in 2026 ↗

January 11, 2026

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗

Topics ETFs Initial Public Offering

January 05, 2026

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

1 High-Flying Stock on Our Watchlist and 2 We Question

January 04, 2026

The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026

January 02, 2026

As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and...

Via MarketMinute

Topics Economy Intellectual Property

2 Russell 2000 Stocks Worth Investigating and 1 We Avoid

January 01, 2026

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher...

Nasdaq Bears Dig In: Short Interest Hits Record 18.38 Billion Shares Amid Valuation Anxiety

December 24, 2025

As the final trading days of 2025 approach, the Nasdaq has reached a staggering milestone that has both bulls and bears on edge. According to the latest settlement data released on December 15, 2025,...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Hims & Hers Hit A GLP-1 Speed Bump This Year — But Growth Is Just Cooling, Not Cracking ↗

December 24, 2025

Hims & Hers has drawn scrutiny for selling compounded GLP-1 treatments – lower-cost, unapproved alternatives to blockbuster weight-loss drugs made by Eli Lilly and Novo Nordisk.

Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline.

3 Profitable Stocks for Long-Term Investors

December 23, 2025

Amazon and Hims & Hers look like good picks for 2026.

2 Top Stocks to Buy With $500 Right Now ↗

December 19, 2025

These are three stocks I am looking to buy.

Topics Artificial Intelligence Economy Stocks

3 Stocks High on My Watch List to Buy ↗

December 17, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 That Underwhelm

December 15, 2025

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and...

1 Stock Under $50 with Exciting Potential and 2 We Brush Off

December 11, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

5 High Short-Interest Stocks to Buy Before Q1 2026 ↗

December 09, 2025

Via MarketBeat

2 Cash-Producing Stocks to Keep an Eye On and 1 That Underwhelm

December 04, 2025

The healthcare industry is ripe for disruption.

Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip? ↗

November 26, 2025

Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’ ↗

November 25, 2025

Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector.

Alignment Healthcare, Hims & Hers Health, Surgery Partners, Guardant Health, and Pediatrix Medical Group Stocks Trade Up, What You Need To Know

Hims, Block, and NRG Just Launched Huge Stock Buybacks ↗

November 24, 2025

Via MarketBeat

November 24, 2025

A number of stocks jumped in the afternoon session after a Politico report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies. The proposal would extend subsidies...

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Topics Economy

1 Small-Cap Stock with Exciting Potential and 2 We Avoid

November 23, 2025

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining...

MarketBeat Week in Review – 11/17 - 11/21 ↗

November 22, 2025

Via MarketBeat

2 Cash-Heavy Stocks with Competitive Advantages and 1 We Find Risky

November 21, 2025